Initial treatment of cryptococcal meningitis in AIDS

Southeast Asian J Trop Med Public Health. 2005 Jan;36(1):170-3.

Abstract

The comparison of initial treatment with amphotericin B (0.7 mg/kg/d) plus rifampin (600 mg/d) with amphotericin B (0.7 mg/kg/d) alone for 2 weeks, both followed by fluconazole (400 mg/ d) for 8 weeks in the acute treatment of cryptococcal meningitis in AIDS by an open- randomized, controlled, prospective clinical trial is reported. Twenty patients were enrolled in each group. There were no significant differences between the groups in regard to a negative CSF culture for Cryptococcus neoformans in the 2nd and 10th weeks of treatment, time until normal body temperature after treatment, number of patients who died, and persistence of high CSF pressure after completion of treatment. Elevated intracranial pressure was an important factor associated with the patients who died. These results indicate that the combination of amphotericin B plus rifampin is not superior to amphotericin B alone.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy*
  • Adult
  • Amphotericin B / therapeutic use*
  • Antifungal Agents / therapeutic use*
  • Cryptococcus neoformans
  • Enzyme Inhibitors / therapeutic use*
  • Female
  • Fluconazole / therapeutic use*
  • Humans
  • Male
  • Meningitis, Cryptococcal / drug therapy*
  • Prospective Studies
  • Rifampin / therapeutic use*

Substances

  • Antifungal Agents
  • Enzyme Inhibitors
  • Amphotericin B
  • Fluconazole
  • Rifampin